title: The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patients.
abstract: HIV reservoirs persistence despite antiretroviral therapy (ART) might be related to persistent immune activation and residual HIV production, requiring further therapeutic strategies. We demonstrated that the tyrosine kinase inhibitor (TKI) Dasatinib, used for chronic myeloid leukaemia, significantly blocks in vitro HIV1 production by 3.4 logs in HIV1-infected primary CD4 T lymphocytes, by inhibiting cell activation and proliferation, without cell toxicity. This molecule deserves to be investigated further for HIV cure strategies to hinder persistent immune activation and residual viral production.
authors.affiliation: aUPMC Univ Paris 06, UMR-S945 bInserm, U945, Laboratory of Immunity and Infection, Paris, France cUniversità Vita-Salute, San Raffaele Scientific Institute, Milan, Italy dORVACS, Hospital Pitié-Salpêtrière eUPMC Univ Paris 06, UMR-S943, Epidemiology, Therapeutics Strategies and Clinical Virology in HIV Infection, Paris, France fInserm, U943, Epidemiology, Therapeutics Strategies and Clinical Virology in HIV Infection gAP-HP, Hospital Pitié-Salpêtrière Hospital, Department of Virology hAP-HP, Hospital Pitié-Salpêtrière Hospital, Department of Infectious and Tropical Diseases, Paris, France.
authors.forename: Manuela
authors.initials: M
authors.lastname: Pogliaghi
authors.forename: Laura
authors.initials: L
authors.lastname: Papagno
authors.forename: Sidonie
authors.initials: S
authors.lastname: Lambert
authors.forename: Ruxandra
authors.initials: R
authors.lastname: Calin
authors.forename: Vincent
authors.initials: V
authors.lastname: Calvez
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
authors.forename: Brigitte
authors.initials: B
authors.lastname: Autran
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects* / Q000821:virology*; D002478:Cells, Cultured; D000069439:Dasatinib; D015658:HIV Infections / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D011743:Pyrimidines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D019380:Anti-HIV Agents; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib